SUN PHARMACEUTICAL INDUSTRIES
|
SUN PHARMACEUTICAL INDUSTRIES Last 5 Year Financial Ratios History
[Consolidated]
| Mar2024 | Mar2023 | Mar2022 | Mar2021 | Mar2020 | |
|---|---|---|---|---|---|
| Operational & Financial Ratios | |||||
| Earnings Per Share (Rs) | 39.91 | 35.32 | 13.64 | 12.10 | 15.69 |
| CEPS(Rs) | 50.87 | 46.22 | 23.13 | 18.19 | 26.01 |
| DPS(Rs) | 13.50 | 11.50 | 10.00 | 7.50 | 4.00 |
| Book NAV/Share(Rs) | 265.36 | 233.38 | 200.11 | 193.65 | 188.66 |
| Tax Rate(%) | 12.98 | 9.01 | 24.00 | 18.39 | 16.42 |
| Margin Ratios | |||||
| Core EBITDA Margin(%) | 26.29 | 26.40 | 14.71 | 13.78 | 11.74 |
| EBIT Margin(%) | 23.35 | 21.83 | 6.86 | 4.78 | 8.94 |
| Pre Tax Margin(%) | 22.86 | 21.44 | 6.67 | 4.55 | 8.43 |
| PAT Margin (%) | 19.89 | 19.51 | 5.07 | 3.72 | 7.05 |
| Cash Profit Margin (%) | 25.17 | 25.27 | 8.26 | 7.10 | 10.50 |
| Performance Ratios | |||||
| ROA(%) | 12.17 | 11.87 | 5.20 | 3.54 | 6.58 |
| ROE(%) | 16.13 | 16.46 | 7.21 | 4.98 | 9.66 |
| ROCE(%) | 17.60 | 17.24 | 9.28 | 5.66 | 10.07 |
| Asset Turnover(x) | 0.61 | 0.61 | 1.03 | 0.95 | 0.93 |
| Sales/Fixed Asset(x) | 1.11 | 1.07 | 1.81 | 1.74 | 1.78 |
| Working Capital/Sales(x) | 1.83 | 2.20 | 3.81 | 4.30 | 3.73 |
| Efficiency Ratios | |||||
| Fixed Capital/Sales(x) | 0.90 | 0.93 | 0.55 | 0.58 | 0.56 |
| Receivable days | 85.38 | 91.17 | 53.09 | 54.88 | 56.22 |
| Inventory Days | 76.70 | 80.83 | 48.68 | 50.10 | 48.40 |
| Payable days | 194.01 | 174.10 | 149.21 | 158.71 | 152.86 |
| Valuation Parameters | |||||
| PER(x) | 40.60 | 27.84 | 67.07 | 49.38 | 22.44 |
| PCE(x) | 31.86 | 21.27 | 39.55 | 32.85 | 13.54 |
| Price/Book(x) | 6.11 | 4.21 | 4.57 | 3.09 | 1.87 |
| Yield(%) | 0.83 | 1.17 | 1.09 | 1.26 | 1.14 |
| EV/Net Sales(x) | 7.86 | 5.38 | 5.57 | 4.20 | 2.63 |
| EV/Core EBITDA(x) | 26.51 | 19.24 | 19.03 | 15.10 | 11.32 |
| EV/EBIT(x) | 33.65 | 24.67 | 46.73 | 47.88 | 16.25 |
| EV/CE(x) | 5.73 | 3.80 | 3.22 | 2.20 | 1.33 |
| M Cap / Sales | 8.02 | 5.37 | 5.68 | 4.28 | 2.57 |
| Growth Ratio | |||||
| Net Sales Growth(%) | 10.51 | 13.53 | 15.39 | 2.01 | 12.98 |
| Core EBITDA Growth(%) | 17.07 | 8.50 | 21.36 | 22.31 | 3.99 |
| EBIT Growth(%) | 18.22 | 107.88 | 56.71 | -44.64 | 21.69 |
| PAT Growth(%) | 12.70 | 151.36 | 49.07 | -45.43 | 30.46 |
| EPS Growth(%) | 13.01 | 158.91 | 12.70 | -22.87 | 41.25 |
| Financial Stability Ratios | |||||
| Total Debt/Equity(x) | 0.04 | 0.11 | 0.02 | 0.08 | 0.18 |
| Current Ratio(x) | 2.56 | 2.00 | 2.03 | 1.89 | 2.02 |
| Quick Ratio(x) | 1.98 | 1.47 | 1.51 | 1.33 | 1.51 |
| Interest Cover(x) | 47.50 | 55.70 | 36.19 | 20.79 | 17.55 |
| Total Debt/Mcap(x) | 0.01 | 0.03 | - | 0.03 | 0.10 |
Compare Financial Ratios of peers of SUN PHARMACEUTICAL INDUSTRIES
| Peers & Returns | Market Capitalization | 1 Week | 1 Month | 1 Year | ||
| SUN PHARMACEUTICAL INDUSTRIES | ₹457,018.7 Cr | -2% | 4.3% | 65.1% | Stock Analytics | |
| DIVIS LABORATORIES | ₹143,952.0 Cr | -0.5% | 6.4% | 44.2% | Stock Analytics | |
| CIPLA | ₹131,056.0 Cr | -2.9% | -1.8% | 39.5% | Stock Analytics | |
| DR REDDYS LABORATORIES | ₹110,731.0 Cr | -1.8% | -2.2% | 20.6% | Stock Analytics | |
| ZYDUS LIFESCIENCES | ₹105,745.0 Cr | -1.6% | -6.3% | 73.8% | Stock Analytics | |
| MANKIND PHARMA | ₹102,507.0 Cr | 0.7% | 8.1% | 41.1% | Stock Analytics | |
SUN PHARMACEUTICAL INDUSTRIES Share Price vs Sensex
| Share Price Returns(%) | 1 Week | 1 Month | 1 Year |
| SUN PHARMACEUTICAL INDUSTRIES | -2% |
4.3% |
65.1% |
| SENSEX | -5.3% |
-1.6% |
23.1% |
You may also like the below Video Courses
